In a world-first, doctors at La Paz Public University Hospital in Madrid have successfully treated a critically ill 11-year-old girl with a rare and often deadly autoimmune disease using CAR-T cell therapy – a technique previously reserved for aggressive blood cancers.
The game-changing results, detailed in the prestigious medical journal Med, marks a pivotal moment not only for Spanish medicine but for global healthcare.
The child was battling anti-MDA5 dermatomyositis, a condition so rare it affects roughly one in a million people and is known for triggering catastrophic lung failure.
With a mortality rate of up to 66% in the first six months, the young girl’s odds of survival were slim.
Admitted to intensive care in critical condition and with no conventional treatment options left, doctors turned to CAR-T under the grounds of compassionate use.
In what can only be described as a medical moonshot, the team infused her with genetically modified immune cells engineered to hunt down rogue components of her own malfunctioning system.
A year on, the results are staggering: no more immunosuppressants, no more ventilators, and a girl who is steadily regaining strength and independence.
She now breathes unaided during the day and continues to recover her motor skills.
The treatment was a concerted effort by a multidisciplinary team spanning Rheumatology to Pulmonology, all within La Paz’s ecosystem and its affiliated research institute, IdiPAZ.
Help also came from across Spain, including Madrid’s Niño Jesus Hospital, Barcelona’s Hospital Clinic and the National Cancer Research Centre.
The recovery of the girl could see the CAR-T treatment applied to other conditions.
What is CAR-T therapy?
CAR-T treatment, or Chimeric Antigen Receptor T-cell therapy, is a type of personalised immunotherapy that uses a patient’s own immune cells to fight disease – most commonly certain cancers, and now, increasingly, severe autoimmune diseases.
How it works:
- Collection: T-cells (a type of white blood cell) are taken from the patient’s blood.
- Engineering: In a lab, the T-cells are genetically modified to produce special receptors on their surface. These receptors are called chimeric antigen receptors (CARs), which allow the T-cells to recognise and attack specific diseased cells (e.g. cancer cells or faulty immune cells).
- Multiplication: The modified T-cells are grown in large numbers.
- Infusion: These ‘supercharged’ CAR-T cells are infused back into the patient, where they hunt and destroy target cells.
Originally for:
- Blood cancers like leukemia and lymphoma, especially when other treatments fail.
Now expanding to:
- Autoimmune diseases, such as lupus or, in the recent Spanish case, a rare and deadly form of dermatomyositis.
Pros:
- Potentially curative in cases where other treatments fail.
- A one-time treatment (in many cases).
- Personalised to the patient’s immune system.
Cons:
- Very expensive.
- Can have serious side effects, including cytokine release syndrome (a massive immune reaction).
- Still relatively new, especially outside of cancer treatment.
